A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Tumor

Interventions

DRUG: ipilimumab
DRUG: nivolumab
DRUG: ENHANZE (rHuPH20)
DRUG: nivolumab

Sponsor

Bristol-Myers Squibb